Crystagen 20mg
Janoshik
Batch CRYS-CA-26F-01
Crystagen
Peptide Bioregulator
Also known as Glu-Asp-Pro (EDP)
Crystagen is a short synthetic peptide of the bioregulator class, supplied as the tripeptide Glu-Asp-Pro and studied in research on immune-tissue models.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Crystagen is a short synthetic peptide of the bioregulator class, supplied as the tripeptide Glu-Asp-Pro and studied in research on immune-tissue models.
Published work addresses the sequence in the context of spleen and immune-cell ageing rather than the trade name.
Third-party tested for purity, ID, quantity.
Crystagen sits within the family of short regulatory peptides investigated for tissue-directed activity in immune research models. Studies have examined immunoprotective activity of short peptides in spleen tissue during ageing, and the broader role of such peptides in directing cell differentiation.
The compound-specific literature is thin. Most available research addresses the short-peptide class collectively rather than this sequence in isolation.
Crystagen emerged from the Russian peptide-bioregulator research programme, which characterized a series of tissue-directed short peptides intended to model endogenous regulatory fragments.
Published investigation has remained largely confined to immune-tissue culture and ageing models.
Research relevant to Crystagen centers on short-peptide immunoprotective activity in spleen tissue during ageing and on peptide regulation of cell differentiation. Reference support is thin relative to better-characterized compounds.
3 of the 4 areas below are addressed directly by a paper cited on this page.
Immune-tissue bioregulator models
No paper cited on this page reports on immune, tissue or bioregulator. This heading marks where Crystagen is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Spleen and lymphoid ageing research
Addressed on this page by Сhervyakova 2014. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Сhervyakova, NA. et al. (2014) — Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process
Peptide-directed cell differentiation
Addressed on this page by Khavinson 2020, Сhervyakova 2014. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, V. et al. (2020) — Peptide Regulation of Cell Differentiation
- Сhervyakova, NA. et al. (2014) — Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process
Short-peptide gene-regulation studies
Addressed on this page by Khavinson 2020, Сhervyakova 2014. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, V. et al. (2020) — Peptide Regulation of Cell Differentiation
- Сhervyakova, NA. et al. (2014) — Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process
The references section of this page cites 2 primary papers published between 2014 and 2020 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Crystagen, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Crystagen is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under immune-tissue bioregulator models, spleen and lymphoid ageing research and peptide-directed cell differentiation.
The 2 papers cited on this page, published between 2014 and 2020 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented alongside compounds with decades of published research, as though the evidence base is comparable.
It is not. Crystagen rests on 2 cited papers (between 2014 and 2020). A record that thin cannot support conclusions about mechanism, effect or safety, and the honest reading is that this compound has been studied very little rather than studied and validated.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for Crystagen is per lot, not per product. The current 20mg lot CRYS-CA-26F-01 returned 97.646% purity, 21.42 mg measured, 107.1% of the labelled 20 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is Crystagen; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Crystagen, this lot measured 107.1% of its labelled 20 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for Crystagen. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Crystagen in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
Crystagen is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 3 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (20mg / Single Vial, 20mg / 5-Pack, 20mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of Crystagen. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99